-
Mashup Score: 292024 Patient Education Ambassadors Program | CancerGRACE - 2 month(s) ago
Applications are now open to oncology fellows and finishing fellows Program Information Form and Application
Source: cancergrace.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Conquer Cancer Announces 2024 Genitourinary Cancers Symposium Merit Awards | Conquer Cancer, the ASCO Foundation - 4 month(s) ago
ALEXANDRIA, Va. — Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2024 Genitourinary Cancers Symposium Merit Awards. These distinguished awards recognize first authors on top-ranking abstracts selected for presentation at the ASCO Genitourinary Cancers Symposium, January 25–27, 2024, in San Francisco, California. The following 32 oncology professionals are recognized for their respective field and research advancements within the cancer care community: Oluseyi
Source: www.conquer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer - 4 month(s) ago
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to an approved precision oncology therapy.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer - 4 month(s) ago
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to an approved precision oncology therapy.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20
Standardized, high-quality PRO data reporting is crucial for patient centered care in the field of oncology, especially in clinical trials that establ…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
🌟In @eClinicalMed🌟w/@MoffittNews @JadChahoud @MParavathaneni @vidhu_joshi @FilipIonescu5 @SavanShahMD @DrJusChadha @sgilbert1973 @AdeleSemaan @philippespiess @BCMHemeOnc @hsafaMD @monicaktamil "15 yrs of PROs in RCTs➡️GU approvals: a systematic review‼️ https://t.co/HlcF60sa2Y https://t.co/Wu1puV0UQq
-
-
Mashup Score: 4A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation - Full Text View - ClinicalTrials.gov - 4 month(s) ago
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity - 5 month(s) ago
Cancer Medicine is an open access, broad-scope oncology journal covering clinical cancer research, cancer biology, cancer prevention, & bioinformatics.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency - 5 month(s) ago
AbstractPurpose:. Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch repair deficiency (MMRD).Patients and Methods:. Twenty patients were screened, and 10 were ultimately included in the response cohort of whom nine had TMB >10 mut/Mb (three initially eligible based on MMRD) and one patient had TMB between 5 and 10 mut/Mb.Results:. Delayed immune responses contributed to best overall response of 50%, improving on initial objective responses (20%) and leading to 2-year overall survival (OS) of 50% [95% confidence interval (CI), 27–93]. Four children, including three with refractory malignant gliomas are in complete remission at a median follow-up of 37 months (range, 32.4–60), culminating in 2-year OS of 43% (95% CI, 18.2–100). Biom
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58Considering molecular alterations as pan-cancer tissue-agnostic targets - Nature Cancer - 5 month(s) ago
Owing to high response rates, the Food and Drug Administration has approved both gene- and immune-targeted drugs for tumor-agnostic, genomic biomarker-based indications, for lethal solid and blood cancers. We posit that current data support tissue-agnostic activity as a paradigm, rather than an exception to the rule.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
🤩Applications are 📭OPEN for @cancerGRACE Ambassador Program! I have been so fortunate to be part of this program w/@IvyLorena_Md @MatthewKurianMD @meera_ragavan @GMRodriguez_MD @jatwanikaran @KaitlinKyi! I encourage you to apply🌟! https://t.co/NNRJJD3jwI https://t.co/sOJHZ4U2YX